JonesResearch downgraded Theratechnologies (THTX) to Hold from Buy after the company announced an agreement with CB Biotechnology, an affiliate of Future Pak, to be acquired for $3.01 per share in cash plus one contingent value right per share for additional aggregate cash payments of up to $1.19 per CVR if certain milestones are achieved.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX: